发帖
雷达卡
Equity | Pan-Europe | Pharmaceuticals
21 September 2009
Competitive trends in key therapy areas – August 09 data
38 pages
Competitive analysis of major therapeutic classes
We provide a monthly competitive market share and growth analysis of the major
therapeutic drug classes of interest to investors for the US market. We use
monthly prescription data for retail and mail order pharmacies sourced from
IMS Health.
New product approvals and patent expiries
We highlight key upcoming product approvals, patent expires and other events
that could impact class dynamics.
Market shares, growth rates and sales forecasts
We highlight category market shares, total prescription growth rates and, where
applicable, Banc of America Securities - Merrill Lynch sales forecasts
US drug market +3% in August (actual), +2.1% (adjusted)
Table 1: Total US market Rx Growth
4Q08 1Q09 2Q09 QTD Aug YoY 12m MAT
Total Market TRx 0.7% -0.2% 3.4% 2.9% 3.0% 1.9%
Total Market NRx 1.4% 0.1% 5.1% 1.6% 3.7% 2.4%
Source: IMS Health
On an actual basis, the US prescription drug market was up 3.0% in August,
versus up 2.8% in July and 1.9% 12 month MAT growth. On an adjusted basis
(which takes into account the number of days in a given month for a year-on-year
comparison), August volumes were up 2.1% versus July volumes up 3.9%.
京公网安备 11010802022788号
